The landscape of continuous glucose monitoring (CGM) has reached a critical evolutionary inflection point. For more than two decades, the sector was defined by an intensive engineering competition focused on physical biosensor attributes: minimising sensor lag, improving mean absolute relative difference accuracy, reducing wearability profiles and ensuring seamless integration with insulin pumps and closed-loop systems. However, as physical sensors have achieved near-perfect

The biopharmaceutical landscape in 2026 has entered a period of profound structural realignment, transitioning from the reactive post-pandemic restructuring of previous years into an era defined by aggressive, data-driven consolidation. Following a record-setting 2025, which saw global pharmaceutical and biotechnology deal values exceed $240 Billion, the current year is characterised by an acceleration of strategic urgency. This momentum is underpinned by a confluence of stab